Shire PLC (NASDAQ:SHPG) has been assigned a $221.00 target price by equities researchers at Royal Bank of Canada in a research report issued on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would suggest a potential upside of 16.32% from the stock’s current price.
A number of other research analysts have also issued reports on SHPG. HSBC Holdings plc lowered shares of Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday. Jefferies Group LLC set a $239.00 price target on shares of Shire PLC and gave the company a “buy” rating in a research note on Saturday, March 18th. Guggenheim restated a “neutral” rating on shares of Shire PLC in a research note on Friday, February 17th. Goldman Sachs Group Inc upped their price objective on shares of Shire PLC from $202.00 to $214.00 and gave the company an “overweight” rating in a report on Monday, April 17th. Finally, Liberum Capital started coverage on shares of Shire PLC in a report on Thursday, March 9th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $221.70.
Shares of Shire PLC (NASDAQ:SHPG) traded down 0.11% during midday trading on Thursday, hitting $189.79. 557,107 shares of the company traded hands. The company has a 50-day moving average price of $176.72 and a 200-day moving average price of $174.43. The stock has a market capitalization of $56.53 billion, a P/E ratio of 194.66 and a beta of 1.53. Shire PLC has a 52 week low of $161.09 and a 52 week high of $209.22.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.22 by $0.41. Shire PLC had a net margin of 1.62% and a return on equity of 14.81%. The business had revenue of $3.57 billion for the quarter. During the same quarter in the previous year, the company posted $2.12 EPS. The company’s revenue for the quarter was up 109.0% compared to the same quarter last year. Analysts anticipate that Shire PLC will post $15.00 earnings per share for the current fiscal year.
The firm also recently announced a dividend, which was paid on Tuesday, April 25th. Stockholders of record on Friday, March 10th were given a $0.771 dividend. This is a boost from Shire PLC’s previous dividend of $0.14. The ex-dividend date was Wednesday, March 8th. Shire PLC’s dividend payout ratio is 51.95%.
Several large investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its stake in Shire PLC by 20.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 4,781,923 shares of the biopharmaceutical company’s stock valued at $927,024,000 after buying an additional 802,411 shares during the last quarter. Lone Pine Capital LLC boosted its stake in Shire PLC by 12.4% in the fourth quarter. Lone Pine Capital LLC now owns 1,904,306 shares of the biopharmaceutical company’s stock valued at $324,456,000 after buying an additional 209,631 shares during the last quarter. Vanguard Group Inc. boosted its stake in Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after buying an additional 13,665 shares during the last quarter. BlackRock Inc. boosted its stake in Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares during the last quarter. Finally, Janus Capital Management LLC boosted its stake in Shire PLC by 10.7% in the first quarter. Janus Capital Management LLC now owns 1,365,226 shares of the biopharmaceutical company’s stock valued at $237,854,000 after buying an additional 132,446 shares during the last quarter. Institutional investors and hedge funds own 22.69% of the company’s stock.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.